Neurocrine Biosciences reports Phase 3 study of valbenazine in DCP did not meet primary or key secondary endpoints

Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance

AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer

Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development

Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents

Hansa Biopharma submits imlifidase Biologics License Application to FDA

T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM

Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP

Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer

Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study

PRISM BioLab partners with Talus Bioscience to address TF and PPI targets

Thryv Therapeutics reports positive Phase 1 results for THRV-1268

Avacta reports tumour shrinkage and 90% disease control rate for AVA6000 in salivary gland cancer patients

Galderma reports data showing rapid itch and sleep improvement with nemolizumab in dermatitis conditions

Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema